{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:38:16Z","timestamp":1787071096585,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Promoter hypermethylation of tumor suppressor genes presents promising markers for lung cancer diagnosis and prognosis. The purpose of this study was to determine the association between the promoter hypermethylation of multiple genes and 5-year survival rate in patients with Non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Primary tumor samples (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 65), corresponding nonmalignant lung tissues (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 65), and circulating blood were obtained from NSCLC patients who underwent curative surgery. Promoter methylation status in seven genes (RASSF1A, CDH13, MGMT, ESR1, DAPK, SOX1, and HOXA9) was quantified by using bisulfite pyrosequencing. Five-year survival data were obtained by a clinician. Cox proportional hazards models were used to analyze the associations between gene methylation status and overall patient survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 5-year survival of the patients with SOX1 aberrant tumor methylation was found to be statistically significantly shorter than for those patients without aberrant tumor methylation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). This effect was independent of TNM stage. No significant survival differences were associated with aberrant methylation in other genes tested in either of the two tissue types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study shows that SOX1 promoter hypermethylation in NSCLC tumors is significantly associated with inferior survival, showing promise as a useful prognostic biomarker in patients with NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_125_20","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T07:32:56Z","timestamp":1629444776000},"page":"1692-1696","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Is hypermethylation of SOX1 gene an independent prognostic marker in surgically resected non-small cell lung cancer?"],"prefix":"10.4103","volume":"18","author":[{"given":"Milica","family":"Kontic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidor","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Bojic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Ognjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SImona","family":"Ognjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-38-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"R2-38-20241021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-38-20241021","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/cncr.21409","article-title":"Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma","volume":"104","author":"Kim","year":"2005","journal-title":"Cancer"},{"key":"R4-38-20241021","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2012.48.5516","article-title":"A prognostic DNA methylation signature for stage i non-small-cell lung cancer","volume":"31","author":"Sandoval","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-38-20241021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14728220902926119","article-title":"Epigenomic targets for the treatment of respiratory disease","volume":"13","author":"Bowman","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"R6-38-20241021","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cllc.2011.11.003","article-title":"Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma","volume":"13","author":"Kontic","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"R7-38-20241021","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/312282a0","article-title":"DNA sequences from the Quagga, an extinct member of the horse family","volume":"312","author":"Higuchi","year":"1984","journal-title":"Nature"},{"key":"R8-38-20241021","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1158\/1078-0432.CCR-09-2819","article-title":"Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer","volume":"16","author":"Saito","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R9-38-20241021","first-page":"4556","article-title":"Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas","volume":"61","author":"Toyooka","year":"2001","journal-title":"Cancer Res"},{"key":"R10-38-20241021","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1038\/sj.onc.1205466","article-title":"K-ras mutations and RASSF1A promoter methylation in colorectal cancer","volume":"21","author":"van Engeland","year":"2002","journal-title":"Oncogene"},{"key":"R11-38-20241021","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/ijc.24896","article-title":"PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients","volume":"126","author":"Buckingham","year":"2010","journal-title":"Int J Cancer"},{"key":"R13-38-20241021","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4161\/epi.20219","article-title":"Key epigenetic changes associated with lung cancer development: Results from dense methylation array profiling","volume":"7","author":"Nelson","year":"2012","journal-title":"Epigenetics"},{"key":"R14-38-20241021","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/ol.2013.1161","article-title":"Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer","volume":"5","author":"Zhao","year":"2013","journal-title":"Oncol Lett"},{"key":"R15-38-20241021","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: Frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-38-20241021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ijc.23957","article-title":"An epigenetic marker panel for screening and prognostic prediction of ovarian cancer","volume":"124","author":"Su","year":"2009","journal-title":"Int J Cancer"},{"key":"R17-38-20241021","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7150\/ijms.7405","article-title":"Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients","volume":"11","author":"Kuo","year":"2014","journal-title":"Int J Med Sci"},{"key":"R18-38-20241021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1476-4598-9-267","article-title":"Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells","volume":"9","author":"Mathews","year":"2010","journal-title":"Mol Cancer"},{"key":"R19-38-20241021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/apm.12719","article-title":"A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer","volume":"125","author":"Lopez","year":"2017","journal-title":"APMIS"},{"key":"R20-38-20241021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/dbio.2000.9883","article-title":"Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators","volume":"15","author":"Bowles","year":"2000","journal-title":"Dev Biol"},{"key":"R21-38-20241021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.stem.2012.12.007","article-title":"The sox family of transcription factors: Versatile regulators of stem and progenitor cell fate","volume":"12","author":"Sarkar","year":"2013","journal-title":"Cell Stem Cell"},{"key":"R22-38-20241021","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1007\/s13277-015-3107-x","article-title":"Epigenetic inactivation of SOX1 promotes cell migration in lung cancer","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_125_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:24Z","timestamp":1787067684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_125_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_125_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}